Fleckenstein AE - Search Results

1

Mechanisms underlying methamphetamine-induced dopamine transporter complex formation.

Hadlock GC, Baucum AJ 2nd, King JL, Horner KA, Cook GA, Gibb JW, Wilkins DG, Hanson GR, Fleckenstein AE. Hadlock GC, et al. Among authors: fleckenstein ae. J Pharmacol Exp Ther. 2009 Apr;329(1):169-74. doi: 10.1124/jpet.108.145631. Epub 2009 Jan 13. J Pharmacol Exp Ther. 2009. PMID: 19141713 Free PMC article.

2

Tolerance to the neurotoxic effects of methamphetamine in young rats.

Riddle EL, Kokoshka JM, Wilkins DG, Hanson GR, Fleckenstein AE. Riddle EL, et al. Among authors: fleckenstein ae. Eur J Pharmacol. 2002 Jan 25;435(2-3):181-5. doi: 10.1016/s0014-2999(01)01592-8. Eur J Pharmacol. 2002. PMID: 11821024

3

Methylenedioxymethamphetamine decreases plasmalemmal and vesicular dopamine transport: mechanisms and implications for neurotoxicity.

Hansen JP, Riddle EL, Sandoval V, Brown JM, Gibb JW, Hanson GR, Fleckenstein AE. Hansen JP, et al. Among authors: fleckenstein ae. J Pharmacol Exp Ther. 2002 Mar;300(3):1093-100. doi: 10.1124/jpet.300.3.1093. J Pharmacol Exp Ther. 2002. PMID: 11861820

4

Phencyclidine increases vesicular dopamine uptake.

Crosby MJ, Hanson JE, Fleckenstein AE, Hanson GR. Crosby MJ, et al. Among authors: fleckenstein ae. Eur J Pharmacol. 2002 Mar 1;438(1-2):75-8. doi: 10.1016/s0014-2999(02)01298-0. Eur J Pharmacol. 2002. PMID: 11906713

5

A single methamphetamine administration rapidly decreases vesicular dopamine uptake.

Brown JM, Riddle EL, Sandoval V, Weston RK, Hanson JE, Crosby MJ, Ugarte YV, Gibb JW, Hanson GR, Fleckenstein AE. Brown JM, et al. Among authors: fleckenstein ae. J Pharmacol Exp Ther. 2002 Aug;302(2):497-501. doi: 10.1124/jpet.302.2.497. J Pharmacol Exp Ther. 2002. PMID: 12130707

6

Differential trafficking of the vesicular monoamine transporter-2 by methamphetamine and cocaine.

Riddle EL, Topham MK, Haycock JW, Hanson GR, Fleckenstein AE. Riddle EL, et al. Among authors: fleckenstein ae. Eur J Pharmacol. 2002 Aug 2;449(1-2):71-4. doi: 10.1016/s0014-2999(02)01985-4. Eur J Pharmacol. 2002. PMID: 12163108

7

Methylphenidate redistributes vesicular monoamine transporter-2: role of dopamine receptors.

Sandoval V, Riddle EL, Hanson GR, Fleckenstein AE. Sandoval V, et al. Among authors: fleckenstein ae. J Neurosci. 2002 Oct 1;22(19):8705-10. doi: 10.1523/JNEUROSCI.22-19-08705.2002. J Neurosci. 2002. PMID: 12351745 Free PMC article.

8

Inhibitory effect of reserpine on dopamine transporter function.

Metzger RR, Brown JM, Sandoval V, Rau KS, Elwan MA, Miller GW, Hanson GR, Fleckenstein AE. Metzger RR, et al. Among authors: fleckenstein ae. Eur J Pharmacol. 2002 Dec 5;456(1-3):39-43. doi: 10.1016/s0014-2999(02)02647-x. Eur J Pharmacol. 2002. PMID: 12450567

9

Ceramide-induced alterations in dopamine transporter function.

Riddle EL, Rau KS, Topham MK, Hanson GR, Fleckenstein AE. Riddle EL, et al. Among authors: fleckenstein ae. Eur J Pharmacol. 2003 Jan 1;458(1-2):31-6. doi: 10.1016/s0014-2999(02)02727-9. Eur J Pharmacol. 2003. PMID: 12498904

10

Methylphenidate alters vesicular monoamine transport and prevents methamphetamine-induced dopaminergic deficits.

Sandoval V, Riddle EL, Hanson GR, Fleckenstein AE. Sandoval V, et al. Among authors: fleckenstein ae. J Pharmacol Exp Ther. 2003 Mar;304(3):1181-7. doi: 10.1124/jpet.102.045005. J Pharmacol Exp Ther. 2003. PMID: 12604695

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

120 results

Search Page